Načítá se...
Efficacy of add-on mepolizumab in adolescents with severe eosinophilic asthma
Adolescents (12–17 years of age) with severe eosinophilic asthma experience frequent exacerbations and reduced lung function leading to poor health-related quality of life. Mepolizumab is approved for add-on maintenance therapy in patients with severe eosinophilic asthma ≥ 6 years of age in the EU a...
Uloženo v:
| Vydáno v: | Allergy Asthma Clin Immunol |
|---|---|
| Hlavní autoři: | , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
BioMed Central
2019
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6724286/ https://ncbi.nlm.nih.gov/pubmed/31507641 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13223-019-0366-x |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|